Abstract
The discovery of new cancer therapeutics has seen a significant shift towards
biologicals as an alternative to small molecule drugs. Alternative binding
peptide molecules, derived from combinatorial scaffold libraries, are now
challenging traditional antibodies. This report identifies the competitive
terrain for cancer therapeutic peptides to be wide open from a compound
perspective and the opportunity for peptide drugs to challenge other
biologicals such as antibodies is real and significant.
This report includes defined and up to date development strategies for 92
cancer therapeutic peptide drugs (>170 projects) within the portfolio of 70
investigators, from Ceased to Marketed. In total the report assesses 30
different cancer indications. The report is written for you to understand and
assess the impact of competitor entry and corresponding changes to development
strategies for your own portfolio products. It serves as an external
commercial advocate for pharmaceutical companies' portfolio planning and new
product planning by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug' s properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report will also be an important part of creating and implementing a
market development plan for any cancer therapeutic peptide drugs to ensure
that the optimal market conditions exist by the time the product is
commercialized.
| 
View Cart
